It is the vitamin everyone knows, and the one surrounded by the most myths, starting with the common cold. The reference Cochrane review gives precise figures, the EU authorises a list of claims, and each dosage form has its own stability constraints. Here is what a brand should know before launching its vitamin C, from the Irati Production R&D team.
Contact us
The Cochrane review by Harri Hemilä and Elizabeth Chalker, published in 2013, pooled all placebo-controlled trials using at least 200 mg of vitamin C a day. Across 29 comparisons and 11,306 participants, regular intake did not reduce the number of colds in the general population. Across 31 comparisons and 9,745 episodes, however, it shortened colds by 8% in adults and 14% in children.
One subgroup stands out: in 598 marathon runners, skiers and soldiers on subarctic exercises, the risk of a cold was roughly halved. Taking vitamin C once a cold has started showed no consistent effect. The lesson for brands: vitamin C sells as a regular routine, not as a last-minute remedy.

Vitamin C has one of the longest lists of claims under Regulation (EU) No 432/2012. From 12 mg per daily portion, 15% of the 80 mg reference value, vitamin C:
One claim builds directly on the trials in athletes: vitamin C contributes to maintaining the normal function of the immune system during and after intense physical exercise. The condition is strict: 200 mg a day in addition to the usual diet. It is a strong argument for a sports range, provided the dose is respected and the target audience genuinely trains hard.
For a winter formula, vitamin C is often paired with zinc and vitamin D, which also carry immune system claims. See our guide to choosing a supplement format.
Vitamin C is fragile: it oxidises with heat, light and moisture. Each form needs a technical answer.
There is still no harmonised EU maximum level for vitamin C in food supplements. EFSA has not set a tolerable upper intake level for lack of sufficient data, and notes that supplemental intakes up to about 1 g a day, on top of the diet, have no known adverse effects. Above that, digestive discomfort may occur. Most formulas on the market provide between 80 and 500 mg a day. Explore our tablet manufacturing.
Hemilä H, Chalker E, Vitamin C for preventing and treating the common cold, Cochrane Database Syst Rev 2013;(1):CD000980. EFSA, Tolerable upper intake levels for vitamins and minerals, 2006. Regulation (EU) No 432/2012.

Irati Production manufactures vitamin C as tablets, chewable tablets, capsules, powders and pectin-based gummies, alone or with zinc and vitamin D, on an ISO 22000 certified, HACCP-based, FDA-registered site.
Not in the general population. The 2013 Cochrane review shows that regular intake of at least 200 mg a day does not reduce the number of colds, but shortens them by 8% in adults and 14% in children. In people under intense physical stress, the risk is roughly halved.
From 12 mg per portion, vitamin C contributes to the normal function of the immune system, to normal collagen formation for skin, to the reduction of tiredness and fatigue, increases iron absorption and protects cells from oxidative stress, among other authorised claims.
The reference value is 80 mg a day. Most formulas provide 80 to 500 mg. The intense exercise claim requires 200 mg a day on top of the usual intake.
Yes. Irati Production manufactures pectin-based gummies containing vitamin C, accounting for its heat sensitivity to guarantee the dose until the best-before date.
A tablet delivers a high dose in a small volume; a powder stick pack mixes into water and suits morning routines. Chewable tablets suit children and people who dislike swallowing tablets.
Irati Production manufactures vitamin C as tablets, chewables, capsules, powders and pectin-based gummies for brands in Saumur, France, as standard or custom formulas.
The information in this article is general and does not constitute regulatory advice. Each formula undergoes a technical and regulatory feasibility study.
Format, dose, combinations: let's talk about your product.
Contact us